How are energy investors positioned?
Investing.com -- Shares of Ambu A/S (CSE:AMBUb) rose on Friday after the Danish medical device maker posted higher third-quarter revenue, raised its full-year sales outlook and cut its cash flow forecast.
Ambu lifted its guidance for full-year organic revenue growth to 12-14%, up from 11-14%, and maintained its EBIT margin target of 13-15%.
The company lowered its free cash flow assumption to about DKK 400 million from more than DKK 500 million.
Free cash flow in the quarter came to DKK 128 million, down from DKK 163 million, while the nine-month total dropped to DKK 277 million from DKK 426 million.
Revenue for the quarter ended June 30 increased to DKK 1.51 billion from DKK 1.38 billion a year earlier, equal to 12% organic growth and 9% reported growth.
Net profit fell to DKK 123 million from DKK 134 million, while earnings per share slipped to DKK 0.46 from DKK 0.50.
Operating profit before special items declined to DKK 170 million from DKK 178 million, with the EBIT margin narrowing to 11.3% from 12.9%.
Gross margin dropped to 58.9% from 60.2%, weighed by foreign exchange effects and tariff costs. EBITDA before special items was DKK 263 million, compared with DKK 267 million.
By business line, Endoscopy Solutions rose 15.9% organically, with pulmonology up 11.2% and urology, ENT and gastroenterology up 20.8%.
Anesthesia and Patient Monitoring grew 6.4% organically. Geographically, North America advanced 12.8%, Europe climbed 11.5% and Rest of World increased 7.9%.
For the first nine months of the fiscal year, revenue rose to DKK 4.57 billion from DKK 4 billion, with EBIT before special items increasing to DKK 637 million from DKK 498 million and the margin improving to 13.9% from 12.4%. Net profit was DKK 494 million, up from DKK 370 million a year earlier.